Bivalent vaccine effectiveness against anal HPV positivity among female STI clinic visitors in the Netherlands
Menée aux Pays-Bas auprès de 548 femmes âgées de 16 à 24 ans, cette étude analyse l'efficacité d'un vaccin bivalent anti-papillomavirus humain contre les infections anales liées à HPV
HPV vaccines are indicated for anal cancer prevention, but evidence for vaccine effectiveness (VE) against anal HPV infections among women is limited. We estimated the VE (≥1 dose) against anal HPV positivity of the bivalent vaccine, whose target types HPV16/18 are associated with ~90% of HPV-related anal cancers. Among 548 16- to 24-year-old female STI clinics visitors who provided an anal swab as part of a repeated cross-sectional survey, VE against HPV16/18 was 89.9% (95%CI 63.0%–97.2%). Type-specific VE correlated well with VE against cervicovaginal HPV (Spearman correlation 0.76), suggesting comparable effectiveness of HPV16/18 vaccination against genital and anal infections.